The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Flagged first, then by citations
2 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 1,007
Lung carcinogenesis by tobacco smoke
Hecht, S. S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27816 · Cited by 502
Zhu, C., Ding, K., Strumpf, D., Weir, B. A., Meyerson, M. M., Pennell, N. A., Thomas, R. K., Naoki, K., Ladd‐Acosta, C., Liu, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4325 · Cited by 467
Self-citationMicrodroplet-based PCR enrichment for large-scale targeted sequencing
Tewhey, R., Warner, J. B., Nakano, M., Libby, B., Medkova, M., David, P. H., Kotsopoulos, S. K., Samuels, M. L., Hutchison, J. B., Larson, J. W., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1583 · Cited by 454
“(6) Purified genomic DNA is mixed together with all of the components of the PCR reaction (DNA polymerase, dNTPs and buffer) except for the PCR primers.”
ATM Mutations in Cancer: Therapeutic Implications
Choi, M. P., Kipps, T. J., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0945 · Cited by 475
Role of ABL family kinases in cancer: from leukaemia to solid tumours
Greuber, E. K., Smith-Pearson, P., Wang, J., & Pendergast, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3563 · Cited by 432
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 465
Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203530109 · Cited by 441
Self-citationYoshizawa, A., Sumiyoshi, S., Sonobe, M., Kobayashi, M., Fujimoto, M., Kawakami, F., Tsuruyama, T., Travis, W. D., Date, H., & Haga, H. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182769aa8 · Cited by 439
Self-citationDe Novo Discovery of Mutated Driver Pathways in CancerPreprint
Vandin, F., Upfal, E., & Raphael, B. J. (2011) · Genome Research · doi:10.1007/978-3-642-20036-6_44 · Cited by 437
Wang, Z. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 448
Algorithms for Detecting Significantly Mutated Pathways in Cancer
Vandin, F., Upfal, E., & Raphael, B. J. (2011) · Journal of Computational Biology · doi:10.1089/cmb.2010.0265 · Cited by 436
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Santos, A., Jung, J. J., Aziz, N., Kissil, J. L., & Puré, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38988 · Cited by 436
Eph Receptor Signaling and EphrinsPreprint
Lisabeth, E. M., Falivelli, G., & Pasquale, E. B. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009159 · Cited by 448
Schabath, M. B., Welsh, E. A., Fulp, W. J., Chen, L., Teer, J. K., Thompson, Z., Engel, B. E., Xie, M., Berglund, A., Creelan, B., et al. (2015) · Oncogene · doi:10.1038/onc.2015.375 · Cited by 419
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O. V., Zoete, V., et al. (2011) · Nature Genetics · doi:10.1038/ng.1026 · Cited by 426
Human cancers express mutator phenotypes: origin, consequences and targeting
Loeb, L. A. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3063 · Cited by 402
Dias-Santagata, D. C., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J. E., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 393
Clinical Outcomes and Correlates of TP53 Mutations and CancerPreprint
Robles, A. I., & Harris, C. C. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001016 · Cited by 397
TP53 Mutations in Nonsmall Cell Lung Cancer
Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 404
Alterations of the Notch pathway in lung cancer
Westhoff, B., Colaluca, I. N., D’Ario, G., Donzelli, M., Tosoni, D., Volorio, S., Pelosi, G., Spaggiari, L., Mazzarol, G., Viale, G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907781106 · Cited by 388
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
Tumor Purity as an Underlying Key Factor in Glioma
Zhang, C., Cheng, W., Ren, X., Wang, Z., Liu, X., Li, G., Han, S., Jiang, T., & Wu, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2598 · Cited by 377
Inhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 401
Discoidin domain receptor tyrosine kinases: new players in cancer progression
Valiathan, R. R., Marco, M., Leitinger, B., Kleer, C. G., & Fridman, R. A. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9346-z · Cited by 384
Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S. K., Reczek, E. E., Raedt, T. D., Guney, I., Strochlic, D. E., MacConaill, L. E., Beroukhim, R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2100 · Cited by 392
Cardarella, S., Ogino, A., Nishino, M., Butaney, M., Shen, J., Lydon, C., Yeap, B. Y., Sholl, L. M., Johnson, B. E., & Janne, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0657 · Cited by 382
Self-citationImplementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370
Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
Islam, S. M. A., Díaz‐Gay, M., Wu, Y., Barnes, M. D., Vangara, R., Bergstrom, E. N., He, Y., Vella, M., Wang, J., Teague, J. W., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100179 · Cited by 364
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 378
Targeting AMPK for cancer prevention and treatment
Li, W., Saud, S. M., Young, M. R., Chen, G., & Hua, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3629 · Cited by 361
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
Therapeutic targeting of EPH receptors and their ligands
Boyd, A., Bartlett, P. F., & Lackmann, M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4175 · Cited by 348
Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution
Yang, D., Jones, M. G., Naranjo, S., Rideout, W. M., Min, K. H., Ho, R., Wu, W., Replogle, J. M., Page, J. L., Quinn, J. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.015 · Cited by 349
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D. W., Widemann, B. C., Kim, M., Dombi, E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 345
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Dar, A. C., Das, T. K., Shokat, K. M., & Cagan, R. L. (2012) · Nature · doi:10.1038/nature11127 · Cited by 337
Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W. J., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 337
Self-citationFunctional impact bias reveals cancer drivers
González-Pérez, A., & López-Bigas, N. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks743 · Cited by 335
Datar, I. J., Sanmamed, M. F., Wang, J., Henick, B. S., Choi, J., Badri, T., Dong, W., Mani, N. L., Toki, M. I., Mejías, L. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4142 · Cited by 330
Guo, G., Gui, Y., Gao, S., Tang, A., Hu, X., Huang, Y., Jia, W., Li, Z., He, M., Sun, L. T., et al. (2011) · Nature Genetics · doi:10.1038/ng.1014 · Cited by 326
Self-citationThe WAVE regulatory complex links diverse receptors to the actin cytoskeleton
Chen, B., Brinkmann, K., Chen, Z., Pak, C. W., Liao, Y., Shi, S., Henry, L., Grishin, N. V., Bogdan, S., & Rosen, M. K. (2014) · Cell · doi:10.1016/j.cell.2013.11.048 · Cited by 323
Taylor, J. G., Cheuk, A., Tsang, P. S., Chung, J., Song, Y., Desai, K. D., Yu, Y., Chen, Q., Shah, K. J., Youngblood, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39703 · Cited by 321
EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
Horn, L., & Pao, W. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6661 · Cited by 317
Self-citationRoles of Fibroblast Growth Factor Receptors in Carcinogenesis
Haugsten, E. M., Więdłocha, A., Olsnes, S., & Wesche, J. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0168 · Cited by 320
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. (2016) · Nature · doi:10.1038/nature16967 · Cited by 316
Molecular Classification of Gastric Cancer: A New Paradigm
Shah, M. A., Khanin, R., Tang, L. H., Janjigian, Y. Y., Klimstra, D. S., Gerdes, H., & Kelsen, D. P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2203 · Cited by 310
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 318
The combined status of ATM and p53 link tumor development with therapeutic responsePreprint
Jiang, H., Reinhardt, H. C., Bártková, J., Tommiska, J., BLOMQVIST, C. P., Nevanlinna, H. A., Bártek, J., Yaffe, M. B., & Hemann, M. T. (2009) · Genes & Development · doi:10.1101/gad.1815309 · Cited by 306
Evidence for type II cells as cells of origin of K-Ras–induced distal lung adenocarcinoma
Xu, X., Rock, J. R., Lu, Y., Futtner, C. R., Schwab, B., Guinney, J., Hogan, B. L. M., & Onaitis, M. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112499109 · Cited by 302
Identification of driver genes in hepatocellular carcinoma by exome sequencing
Cleary, S. P., Jeck, W. R., Zhao, X., Chen, K., Selitsky, S. R., Savich, G. L., Tan, T. X., Wu, M. C., Getz, G. A., Lawrence, M. S., et al. (2013) · Hepatology · doi:10.1002/hep.26540 · Cited by 315
Self-citationWilkerson, M. D., Yin, X., Walter, V., Zhao, N., Cabanski, C. R., Hayward, M. C., Miller, C. R., Socinski, M. A., Parsons, A. M., Thorne, L. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036530 · Cited by 295
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3342 · Cited by 288
Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J. A., Solit, D. B., Paty, P. B., Rohle, D., Vivanco, I., Chmielecki, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900571106 · Cited by 298
Self-citationEmerging common themes in regulation of PIKKs and PI3Ks
Lempiäinen, H., & Halazonetis, T. D. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.281 · Cited by 312
Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T. S. K., Novello, S., O'Byrne, K. J., Stahel, R. A., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 306
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 303
Integrated analysis of germline and somatic variants in ovarian cancer
Kanchi, K., Johnson, K. J., Lu, C., McLellan, M. D., Leiserson, M. D. M., Wendl, M. C., Zhang, Q., Koboldt, D. C., Xie, M., Kandoth, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4156 · Cited by 308
Self-citationPrenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291
Eph Receptors and Ephrins: Therapeutic Opportunities
Barquilla, A., & Pasquale, E. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140226 · Cited by 295
Galan-Cobo, A., Sitthideatphaiboon, P., Qu, X., Poteete, A., Pisegna, M. A., Tong, P., Chen, P.-H., Boroughs, L. K., Rodriguez, M. L. M., Zhang, W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3527 · Cited by 292
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290
Self-citationCancer heterogeneity—a multifaceted view
Melo, F. D. S. E., Vermeulen, L., Fessler, E., & Medema, J. P. (2013) · EMBO Reports · doi:10.1038/embor.2013.92 · Cited by 287
Greulich, H. E., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K., Yun, C., Zhang, X., Lee, S., Cho, J., Ambrogio, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203201109 · Cited by 288
Self-citationATM and ATR signaling at a glance
Awasthi, P., Foiani, M., & Kumar, A. (2015) · Journal of Cell Science · doi:10.1242/jcs.169730 · Cited by 292
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
Dietlein, F., Thelen, L., & Reinhardt, H. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.06.003 · Cited by 290
Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
Doebele, R. C., Lu, X. J. D., Sumey, C. J., Maxson, D. A., Weickhardt, A. J., Oton, A. B., Bunn, P. A., Barón, A. E., Franklin, W. A., Aisner, D. L., et al. (2012) · Cancer · doi:10.1002/cncr.27409 · Cited by 280
Germline BAP1 Mutations Predispose to Renal Cell Carcinomas
Popova, T. G., Hebert, L., Jacquemin, V., Gad, S., Caux‐Moncoutier, V., d’Enghien, C. D., Richaudeau, B., Renaudin, X., Sellers, J., Nicolas, A., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.012 · Cited by 278
The molecular pathology of cancer
Harris, T., & McCormick, F. P. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.41 · Cited by 286
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271
Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers
Reimand, J., & Bader, G. D. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.68 · Cited by 274
Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
Koo, G. C., Tan, S., Tang, T. P. L., Poon, S. L., Allen, G. E., Tan, L. H. C., Chong, S. C., Ong, W. S., Tay, K. K. W., Tao, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0028 · Cited by 277
Girard, N., Deshpande, C. G., Lau, C. C., Finley, D. J., Rusch, V. W., Pao, W. J., & Travis, W. D. (2009) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(10)79482-2 · Cited by 274
Self-citationDawnRank: discovering personalized driver genes in cancer
Hou, J. P., & Ma, J. (2014) · Genome Medicine · doi:10.1186/s13073-014-0056-8 · Cited by 271
Diagnosis and Molecular Classification of Lung Cancer
Rodriguez‐Canales, J., Parra-Cuentas, E. R., & Wistuba, I. I. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_2 · Cited by 292
Self-citationHa, G., Roth, A. J. L., Lai, D., Bashashati, A., Ding, J., Goya, R., Giuliany, R., Rosner, J., Oloumi, A., Shumansky, K., et al. (2012) · Genome Research · doi:10.1101/gr.137570.112 · Cited by 269
Kim, K., Lee, H. W., Lee, H., Kim, S. C., Seo, Y. J., Chung, W., Eum, H. H., Nam, D., Kim, J., Joo, K. M., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0692-3 · Cited by 269
Molecular Pathways: Targeting ATR in Cancer Therapy
Karnitz, L. M., & Zou, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0479 · Cited by 277
Grove, O., Berglund, A. E., Schabath, M. B., Aerts, H. J. W. L., Dekker, A., Wang, H., Velazquez, E. R., Lambin, P., Gu, Y., Balagurunathan, Y., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118261 · Cited by 263
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R. A., Moldovan, C. S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 307
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Kumar, M. S., Hancock, D. C., Molina‐Arcas, M., Steckel, M., East, P., Diefenbacher, M. E., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 269
Koga, T., Suda, K., Fujino, T., Ohara, S., Hamada, A., Nishino, M., Chiba, M., Shimoji, M., Takemoto, T., Arita, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.015 · Cited by 265
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
Mierke, C. T. (2019) · Reports on Progress in Physics · doi:10.1088/1361-6633/ab1628 · Cited by 267
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.014 · Cited by 258
Wang, X., Schoenhals, J. E., Li, A., Valdecanas, D. R., Ye, H., Zang, F., Tang, C. Z., Tang, M., Liu, C., Liu, X., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3142 · Cited by 266
Charrier, J., Durrant, S. J., Golec, J. M. C., Kay, D. P., Knegtel, R. M. A., MacCormick, S., Mortimore, M., O'Donnell, M. E., Pinder, J. L., Reaper, P. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101488z · Cited by 261
Elucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
Self-citationSelecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 257
Sos, M. L., Fischer, S., Ullrich, R. T., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J. M., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 258
Self-citationVillalobos, P. A., & Wistuba, I. I. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.006 · Cited by 268
Self-citationMaldonado, L., Teague, J. E., Morrow, M. P., Jotova, I., Wu, T. ‐., Wang, C., Desmarais, C., Boyer, J., Tycko, B., Robins, H. S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007323 · Cited by 252
Mutational Heterogeneity in Human Cancers: Origin and Consequences
Salk, J. J., Fox, E., & Loeb, L. A. (2009) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102113 · Cited by 266
Molecular Biology of Lung Cancer
Nana-Sinkam, S. P., & Powell, C. A. (2013) · CHEST Journal · doi:10.1378/chest.12-2346 · Cited by 251
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
Jamal‐Hanjani, M., Hackshaw, A., Ngai, Y., Shaw, J., Dive, C., Quezada, S. A., Middleton, G., de Bruin, E. C., Quesne, J. P. C. L., Shafi, S., et al. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001906 · Cited by 247
Molecular pathology of lung cancer: key to personalized medicine
Liang Cheng, C., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Antonio Lopez-beltran, B., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.215 · Cited by 249
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study
Li, Y., Sheu, C., Ye, Y., de Andrade, M., Wang, L., Chang, S., Aubry, M. C., Aakre, J. A., Allen, M. S., Chen, F., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70042-5 · Cited by 252
Self-citationMolecular Biology of Lung Cancer: Clinical Implications
Larsen, J. E., & Minna, J. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.003 · Cited by 251
DuPage, M. J. P., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R. T., Schmidt, L., Crowley, D. G., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244
Therapeutic Targeting of Cancers with Loss of PTEN Function
Dillon, L. M., & Miller, T. W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106100909 · Cited by 246
Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 252
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
